Regulatory considerations for therapeutic use of bacteriophages in the UK
This publication clarifies which regulatory guidelines should be followed, and which apply, in the development of phage therapeutic products.
Latest change: Updated to include reference to draft guidance on quality aspects of phage therapy medicinal products [EMA/CHMP/BWP/1/2024] that was released for consultation in October 2025.
AI Summary
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has released a comprehensive guidance document designed to centralize regulatory requirements for the development of phage therapeutic products. This publication acts as a unified resource for developers navigating the complex regulatory framework governing both licensed and unlicensed medicines. Unlike an enforcement report involving specific company violations or inspection dates, this document focuses on establishing clear standards across the entire product lifecycle, from preclinical research to post-licensure pharmacovigilance. The MHRA acknowledges that while regulatory documentation exists, it is often difficult for developers to locate or interpret; consequently, this consolidation aims to clarify the path to compliance. Key areas addressed include rigorous preclinical testing, safety assessments, and the maintenance of robust monitoring systems once a product enters the market. Developers are expected to follow these consolidated guidelines to ensure their products meet the safety and efficacy standards necessary for patient use. By streamlining access to these regulatory expectations, the MHRA intends to support the advancement of phage therapies and accelerate the delivery of innovative treatments to patients. This centralized approach reduces the burden on developers and ensures a consistent application of medicinal standards within the United Kingdom.
The full document, source attachments, and change history are available on KeyPedia. Sign in to view.